Clinical Trial Update: Efficacy, Safety, and Tolerability of ACZ885 in Patients With Muckle-Wells Syndrome [Phase 3]

View source ↗

Summary

Phase 3 trial update reporting efficacy, safety, and tolerability of ACZ885 (canakinumab) in patients with Muckle-Wells syndrome; results posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Muckle-wells Syndrome

Drugs mentioned

• ACZ885 (canakinumab)

Snippet

Sponsor: Novartis | Conditions: Muckle Wells Syndrome | Phase 3 | Status: COMPLETED | Results posted: 2011-02-11